Bayer AG

Crop Science (~47% of group sales) is inherently seasonal and annual-transactional, with no meaningful backlog or multi-year contract structure. Pharmaceuticals provides some revenue persistence through ongoing patient therapy (particularly Nubeqa and Kerendia for chronic conditions), but the Xarelto U.S. patent expiry in 2025 and Eylea biosimilar pressure demonstrate the structural fragility of blockbuster-dependent pharmaceutical revenue.

Three genuinely uncorrelated segments spanning agricultural technology, specialty pharmaceuticals, and OTC consumer health reduce single-industry exposure. Crop Science remains the largest at ~47% of FY2025 sales, limiting full diversification, and within Pharmaceuticals the near-term profile was historically concentrated in a handful of franchises (Xarelto, Eylea) even as Nubeqa and Kerendia expand the drug mix.

FY2025 group sales were distributed across North America (~37%), Europe/EMEA (~30%), Latin America (~17%), and Asia-Pacific (~16%), with no single country above 40% of revenue. This spread has been sustained across FY2021-FY2025 and reflects Crop Science's strong Latin American grain-belt presence alongside Pharmaceuticals' European and North American franchise distribution.

All three of Bayer's divisions are asset- and labor-intensive; Crop Science requires annual seed production and distribution infrastructure, Pharmaceuticals requires sustained R&D and manufacturing investment, and Consumer Health is effectively a branded FMCG business. The €2 billion DSO savings program targets structural cost removal rather than operating leverage improvement, and EBITDA margins have been under pressure across FY2022-FY2025 rather than expanding on volume growth.

Bayer's revenue comes from annual Crop Science input purchases, branded pharmaceutical prescriptions for chronic disease management, and repeat OTC healthcare purchases; none reaches the level of multi-year contracted or deeply mission-critical revenue. Specialty pharma prescriptions for chronic conditions (prostate cancer, kidney disease) carry meaningful therapy persistence, partially offset by the transactional nature of Consumer Health and seasonal agricultural input spending.